Cingulate Inc.
NASDAQ:CINGBiotechnology
-$0.05 today
- Market cap
- $76.46M
- Beta
- -0.91
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$5.10
Volume 0.95M
Average 0.46M
CING Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Cingulate Inc.NASDAQ: CING
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How CING compares with its peers on the latest reported figures
- CING's LTM Mar 2026 cost of revenue of $0 is the highest of the 2 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding CING) | $0 | — | — | — | |
Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.41M | 9M | 15.49M | 9.45M | 9.77M |
| Selling, General & Admin | 12.27M | 8.51M | 7.27M | 6.2M | 10.16M |
| Operating Expenses | 20.68M | 17.5M | 22.76M | 15.64M | 19.94M |
| Depreciation & Amortization | 708.32K | 394.01K | 582.92K | 653.09K | 540.89K |
| EBITDA | (19.97M) | (17.11M) | (22.18M) | (14.99M) | (19.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (20.68M) | (17.5M) | (22.76M) | (15.64M) | (19.94M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 175 | 775.76K | 0 | 369.27K |
| Interest Expense | 33.41K | 174K | 0 | 0 | 924.45K |
| Other Income / Expenses | (30.59K) | (174.51K) | (775.76K) | (914.63K) | (2.51M) |
| Income Before Tax | (20.71M) | (17.68M) | (23.53M) | (16.56M) | (22.45M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.71M) | (17.68M) | (23.53M) | (16.56M) | (22.45M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (55.80) | (31.20) | (311.99) | (10.20) | (4.13) |
| EPS (Diluted) | (55.80) | (31.20) | (311.99) | (10.20) | (4.13) |
| Weighted Avg Shares | 1.41M | 1.41M | 2.26M | 3.81M | 5.43M |
| Weighted Avg Shares (Diluted) | 1.41M | 1.41M | 2.26M | 3.81M | 5.43M |
Cingulate Inc.
NASDAQ:CING
Intrinsic Alpha fair value
Locked
Current Price
$5.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.